Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.

Area of Science:

• Infectious Diseases
• Pharmacoeconomics
• Clinical Pharmacology

Background:

• Serious bacterial infections often necessitate broad-spectrum injectable antibiotics.
• Evaluating the cost-effectiveness of different antibiotic regimens is crucial for optimizing patient care and resource allocation.

Purpose of the Study:

• To compare the cost-effectiveness of imipenem/cilastatin versus clindamycin plus gentamicin in treating serious bacterial infections.
• To analyze the total treatment costs, including drug acquisition, administration, and monitoring.

Main Methods:

• Retrospective analysis of a previously published clinical trial data.
• Randomized patients received either imipenem/cilastatin or clindamycin plus gentamicin with serum concentration monitoring.
• Cost analysis included antibiotic drugs, administration equipment, staff time, and laboratory assays.

Main Results:

• Imipenem/cilastatin showed significantly higher efficacy and a lower incidence of adverse reactions compared to clindamycin plus gentamicin.
• Despite higher drug costs, imipenem/cilastatin was not more expensive per treatment day.
• The overall cost-effectiveness favored imipenem/cilastatin due to its improved clinical outcomes.

Conclusions:

• Imipenem/cilastatin represents a more cost-effective treatment option for serious bacterial infections compared to clindamycin plus gentamicin.
• The enhanced efficacy and safety profile of imipenem/cilastatin contribute to its superior value in clinical practice.
• These findings support the use of imipenem/cilastatin in settings where broad-spectrum injectable antibiotics are indicated.